AHAbigail Louise Higgins

Abigail Louise Higgins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abigail Louise Higgins has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chiao-Yin Lee

    UCL Queen Square Institute of Neurology, University College London 4 Department of Clinical and Movement Neurosciences London

    2 shared publications
  • Marco Toffoli

    Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London

    2 shared publications
  • Sofia Koletsi

    Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom

    2 shared publications
  • Stephen Mullin

    Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom

    2 shared publications
  • Anthony H V Schapira

    Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, United Kingdom

    1 shared publication
  • Anthony H. V. Schapira

    Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson’s disease-associated GBA gene

    by Marco Toffoli, Xiao Chen, Fritz J. Sedlazeck, Chiao-Yin Lee, Stephen Mullin, Abigail Higgins, Sofia Koletsi, Monica Emili Garcia-Segura, Esther Sammler, Sonja W. Scholz, et al.

    GBA variants carriers are at increased risk of Parkinson’s disease (PD) and Lewy body dementia (LBD). The presence of pseudogene GBAP1 predisposes to structural variants, complicating genetic analysis. We present two methods to resolve recombinant alleles and other variants in GBA: Gauchian, a tool for short-read, whole-genome sequencing data analysis, and Oxford Nanopore sequencing after PCR enrichment. Both methods were concordant for 42 samples carrying a range of recombinants and GBAP1-related mutations, and Gauchian outperformed the GATK Best Practices pipeline. Applying Gauchian to sequencing of over 10,000 individuals shows that copy number variants (CNVs) spanning GBAP1 are relatively common in Africans. CNV frequencies in PD and LBD are similar to controls. Gains may coexist with other mutations in patients, and a modifying effect cannot be excluded. Gauchian detects more GBA variants in LBD than PD, especially severe ones. These findings highlight the importance of accurate GBA analysis in these patients.


  • Open Access

    The Remote Assessment of Parkinsonism Supporting the Ongoing Development of Interventions in Gaucher Disease

    by Abigail Louise Higgins, Marco Toffoli, Stephen Mullin, Chiao-Yin Lee, Sofia Koletsi, Micol Avenali, Fabio Blandini, Anthony Hv Schapira

    Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson's disease (PD). The diagnosis of PD relies upon clinically def... Lay abstract Changes in a gene called GBA cause a rare condition called Gaucher disease and are the most common genetic risk factor for Parkinson's disease (PD). To diagnose PD, patients must show ...


  • Open Access

    The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease – Study Protocol

    by Abigail Louise Higgins, Marco Toffoli, Stephen Mullin, Chiao-Yin Lee, Sofia Koletsi, Micol Avenali, Fabio Blandini, Anthony H V Schapira

    Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson disease. The diagnosis of Parkinson disease relies upon clinically defined motor features which appear after irreversible neurodegeneration. Prodromal symptoms of Parkinson disease may provide a means to predict latent pathology, years before the onset of motor features. Previous work has reported prodromal features of Parkinson disease in GBA mutation carriers, however this has been insufficiently sensitive to identify those that will develop Parkinson disease. The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease (RAPSODI) study assesses a large cohort of GBA mutation carriers, to aid development of procedures for earlier diagnosis of Parkinson disease. Summary Points: The therapeutic focus for Parkinson disease is currently symptomatic, rather than disease-modifying or neuroprotective. Non-motor prodromal features of Parkinson disease may precede the motor symptoms required for clinical diagnosis by several years. GBA mutations, which are associated with Gaucher disease in their biallelic form, have emerged as the most common genetic risk factor for Parkinson Disease. GBA associated PD displays a slightly exaggerated phenotype, including earlier age of onset, enhanced cognitive decline, more severe affective disturbances, and a greater likelihood of manifesting REM Sleep Behaviour Disorder, hyposmia and autonomic dysfunction. The RAPSODI GD study is an annual remote assessment which aims to define the clinical prodrome of PD in a large cohort of GBA mutation carriers, to accurately predict clinical diagnosis. The secondary objectives of RAPSODI GD are to risk stratify homozygote and heterozygote GBA mutation carriers for PD risk, understand the variable penetrance of the GBA associated PD phenotype, and create a platform for the future evaluation of biomarkers of disease. The putative implication of the RAPSODI GD study is to contribute towards earlier diagnosis of GBA associated PD, to provide a timeframe for delivering neuroprotective interventions. Defining prodromal PD in GBA carriers may have wider implications for sporadic PD.